 Adamas Pharmaceuticals, Inc. ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent no. 10,646,456 by the United States Patent and Trademark Office USPTO that covers GOCOVRI amantadine extended release capsules. The new patent covers a method of reducing OFF time and increasing good ON time ON time without troublesome dyskinesia in people with Parkinsons disease PD being treated with levodopa. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. 